Towercrest Capital Management Bristol Myers Squibb CO Transaction History

Towercrest Capital Management

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	SELL	$47.98 - $54.4 $38,623 - $43,792	-805 Reduced 15.16%	4,505 $244,000
Q3 2023 Nov 13, 2023	SELL	$57.89 - $64.73 $1,794 - $2,006	-31 Reduced 0.58%	5,310 $308,000
Q2 2023 Aug 04, 2023	BUY	$63.71 - $70.74 $65,876 - $73,145	1,034 Added 24.01%	5,341 $341,000
Q2 2021 Aug 13, 2021	SELL	$61.91 - $67.42 $11,329 - $12,337	-183 Reduced 4.08%	4,307 $288,000
Q1 2021 May 14, 2021	BUY	$59.34 - $66.74 $266,436 - $299,662	4,490 New	4,490 $283,000
Q3 2020 Nov 13, 2020	SELL	$57.43 - $63.64 $351,241 - $389,222	-6,116 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$54.82 - $64.09 $493 - $576	-9 Reduced 0.15%	6,116 $360,000
Q1 2020 May 14, 2020	SELL	$46.4 - $67.43 $2,134 - $3,101	-46 Reduced 0.75%	6,125 $341,000
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $43,354 - $56,551	881 Added 16.65%	6,171 $397,000
Q2 2019 Aug 14, 2019	BUY	$44.62 - $49.34 $236,039 - $261,008	5,290 New	5,290 $239,000

2,536

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $125B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Towercrest Capital Management, based on Form 13F filings with the SEC.

Stay updated on Towercrest Capital Management with notifications on news.